World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBANDELOW, Borwin
dc.contributor.authorALLGULANDER, Christer
dc.contributor.authorBALDWIN, David S.
dc.contributor.authorCOSTA, Daniel Lucas da Conceicao
dc.contributor.authorDENYS, Damiaan
dc.contributor.authorDILBAZ, Nesrin
dc.contributor.authorDOMSCHKE, Katharina
dc.contributor.authorERIKSSON, Elias
dc.contributor.authorFINEBERG, Naomi A.
dc.contributor.authorHATTENSCHWILER, Josef
dc.contributor.authorHOLLANDER, Eric
dc.contributor.authorKAIYA, Hisanobu
dc.contributor.authorKARAVAEVA, Tatiana
dc.contributor.authorKASPER, Siegfried
dc.contributor.authorKATZMAN, Martin
dc.contributor.authorKIM, Yong-Ku
dc.contributor.authorINOUE, Takeshi
dc.contributor.authorLIM, Leslie
dc.contributor.authorMASDRAKIS, Vasilios
dc.contributor.authorMENCHON, Jose M.
dc.contributor.authorMIGUEL, Euripedes C.
dc.contributor.authorMOLLER, Hans-Jurgen
dc.contributor.authorNARDI, Antonio E.
dc.contributor.authorPALLANTI, Stefano
dc.contributor.authorPERNA, Giampaolo
dc.contributor.authorRUJESCU, Dan
dc.contributor.authorSTARCEVIC, Vladan
dc.contributor.authorSTEIN, Dan J.
dc.contributor.authorTSAI, Shih-Jen
dc.contributor.authorAMERINGEN, Michael Van
dc.contributor.authorVASILEVA, Anna
dc.contributor.authorWANG, Zhen
dc.contributor.authorZOHAR, Joseph
dc.date.accessioned2023-04-14T18:05:48Z
dc.date.available2023-04-14T18:05:48Z
dc.date.issued2023
dc.description.abstractAim This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (published in 2002, revised in 2008). Method A consensus panel of 33 international experts representing 22 countries developed recommendations based on efficacy and acceptability of available treatments. In total, 1007 RCTs for the treatment of these disorders in adults, adolescents, and children with medications, psychotherapy and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medications. Result This paper, Part I, contains recommendations for the treatment of panic disorder/agoraphobia (PDA), generalised anxiety disorder (GAD), social anxiety disorder (SAD), specific phobias, mixed anxiety disorders in children and adolescents, separation anxiety and selective mutism. Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line medications. Cognitive behavioural therapy (CBT) is the first-line psychotherapy for anxiety disorders. The expert panel also made recommendations for patients not responding to standard treatments and recommendations against interventions with insufficient evidence. Conclusion It is the goal of this initiative to provide treatment guidance for these disorders that has validity throughout the world.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipEuropean College of Neuropsychopharmacology (ECNP)
dc.identifier.citationWORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, v.24, n.2, p.79-117, 2023
dc.identifier.doi10.1080/15622975.2022.2086295
dc.identifier.eissn1814-1412
dc.identifier.issn1562-2975
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/53064
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTDeng
dc.relation.ispartofWorld Journal of Biological Psychiatry
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright TAYLOR & FRANCIS LTDeng
dc.subjectAnxiety disorderseng
dc.subjecttreatmenteng
dc.subjectguidelineeng
dc.subjectadolescentseng
dc.subjectchildreneng
dc.subject.otherserotonin reuptake inhibitorseng
dc.subject.otherrandomized controlled-trialeng
dc.subject.otherage-of-onseteng
dc.subject.otherobstructive pulmonary-diseaseeng
dc.subject.othereye-movement desensitizationeng
dc.subject.othercognitive-behavior therapyeng
dc.subject.othermajor depressive disordereng
dc.subject.otherresistant panic disordereng
dc.subject.otherlong-term treatmenteng
dc.subject.otherdouble-blindeng
dc.subject.wosPsychiatryeng
dc.titleWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorderseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countrySingapura
hcfmusp.affiliation.countryGrécia
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryAustrália
hcfmusp.affiliation.countryÁfrica do Sul
hcfmusp.affiliation.countryTaiwan
hcfmusp.affiliation.countryChina
hcfmusp.affiliation.countryIsrael
hcfmusp.affiliation.countryAlemanha
hcfmusp.affiliation.countrySuécia
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryHolanda
hcfmusp.affiliation.countryTurquia
hcfmusp.affiliation.countrySuíça
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryJapão
hcfmusp.affiliation.countryRússia
hcfmusp.affiliation.countryÁustria
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryCoréia do Sul
hcfmusp.affiliation.countryisode
hcfmusp.affiliation.countryisose
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisonl
hcfmusp.affiliation.countryisotr
hcfmusp.affiliation.countryisoch
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisojp
hcfmusp.affiliation.countryisoru
hcfmusp.affiliation.countryisoat
hcfmusp.affiliation.countryisoca
hcfmusp.affiliation.countryisokr
hcfmusp.affiliation.countryisosg
hcfmusp.affiliation.countryisogr
hcfmusp.affiliation.countryisoes
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisoau
hcfmusp.affiliation.countryisoza
hcfmusp.affiliation.countryisotw
hcfmusp.affiliation.countryisocn
hcfmusp.affiliation.countryisoil
hcfmusp.author.externalBANDELOW, Borwin:Univ Med Ctr, Dept Psychiat & Psychotherapy, Gottingen, Germany
hcfmusp.author.externalALLGULANDER, Christer:Uppsala Univ, Dept Med Sci, Psychiat, Uppsala, Sweden
hcfmusp.author.externalBALDWIN, David S.:Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England
hcfmusp.author.externalDENYS, Damiaan:Universitair Med Centra, Afdeling Psychiat, Amsterdam, Netherlands
hcfmusp.author.externalDILBAZ, Nesrin:Uskudar Univ, Tip Fak Psikiyatri ABD, Istanbul, Turkey
hcfmusp.author.externalDOMSCHKE, Katharina:Univ Freiburg, Med Ctr Univ Freiburg, Fac Med, Dept Psychiat & Psychotherapy, Freiburg, Germany
hcfmusp.author.externalERIKSSON, Elias:Univ Gothenburg, Dept Pharmacol, Gothenburg, Sweden
hcfmusp.author.externalFINEBERG, Naomi A.:Univ Hertfordshire, Sch Life & Med Sci, Hatfield, Herts, England
hcfmusp.author.externalHATTENSCHWILER, Josef:Treatment Ctr Anxiety & Depress, Zurich, Switzerland
hcfmusp.author.externalHOLLANDER, Eric:Albert Einstein Coll Med, New York, NY USA
hcfmusp.author.externalKAIYA, Hisanobu:Kyoto Prefactual Med Coll, Dept Psychiat, Kyoto, Japan
hcfmusp.author.externalKARAVAEVA, Tatiana:St Petersburg State Pediat Med Univ, Fed State Budgetary Inst Higher Educ, Minist Hlth, VM Bekhterev Natl Med Res Ctr Psychiat & Neurol, St Petersburg, Russia
hcfmusp.author.externalKASPER, Siegfried:Med Univ Vienna, Clin Div Gen Psychiat, Vienna, Austria
hcfmusp.author.externalKATZMAN, Martin:START Clin, Toronto, ON, Canada; Adler Grad Profess Sch, Toronto, ON, Canada; Northern Ontario Sch Med, Dept Psychiat, Thunder Bay, ON, Canada; Lakehead Univ, Dept Psychol, Thunder Bay, ON, Canada
hcfmusp.author.externalKIM, Yong-Ku:Korea Univ, Coll Med, Dept Psychiat, Seoul, South Korea
hcfmusp.author.externalINOUE, Takeshi:Tokyo Med Univ, Dept Psychiat, Tokyo, Japan
hcfmusp.author.externalLIM, Leslie:Singapore Gen Hosp, Dept Psychiat, Singapore, Singapore
hcfmusp.author.externalMASDRAKIS, Vasilios:Natl & Kapodistrian Univ Athens, Eginit Hosp, Dept Psychiat 1, Med Sch, Athens, Greece
hcfmusp.author.externalMENCHON, Jose M.:Univ Barcelona, Bellvitge Univ Hosp, Dept Psychiat, IDIBELL,Cibersam, Barcelona, Spain
hcfmusp.author.externalMOLLER, Hans-Jurgen:Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
hcfmusp.author.externalNARDI, Antonio E.:Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil
hcfmusp.author.externalPALLANTI, Stefano:Univ Florence, Ist Die Neurosci, Florence, Italy
hcfmusp.author.externalPERNA, Giampaolo:Humanitas Univ Pieve Emanuele, Dept Biol Sci, Milan, Italy
hcfmusp.author.externalRUJESCU, Dan:Med Univ Vienna, Clin Div Gen Psychiat, Vienna, Austria
hcfmusp.author.externalSTARCEVIC, Vladan:Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Nepean Clin Sch, Sydney, NSW, Australia
hcfmusp.author.externalSTEIN, Dan J.:Univ Cape Town, Dept Psychiat, SA MRC Unit Risk & Resilience Mental Disorders, Cape Town, South Africa; Univ Cape Town, Neurosci Inst, Cape Town, South Africa
hcfmusp.author.externalTSAI, Shih-Jen:Taipei Vet Gen Hosp, Dept Psychiat, Taipei, Taiwan
hcfmusp.author.externalAMERINGEN, Michael Van:McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada
hcfmusp.author.externalVASILEVA, Anna:II Mechnikov North Western State Med Univ, VM Bekhterev Natl Med Res Ctr Psychiat & Neurol, Minist Hlth, St Petersburg, Russia
hcfmusp.author.externalWANG, Zhen:Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai, Peoples R China
hcfmusp.author.externalZOHAR, Joseph:Chaim Sheba Med Ctr, Tel Aviv, Israel
hcfmusp.citation.scopus23
hcfmusp.contributor.author-fmusphcDANIEL LUCAS DA CONCEICAO COSTA
hcfmusp.contributor.author-fmusphcEURIPEDES CONSTANTINO MIGUEL FILHO
hcfmusp.description.beginpage79
hcfmusp.description.endpage117
hcfmusp.description.issue2
hcfmusp.description.volume24
hcfmusp.origemWOS
hcfmusp.origem.pubmed35900161
hcfmusp.origem.scopus2-s2.0-85135149080
hcfmusp.origem.wosWOS:000832505700001
hcfmusp.publisher.cityABINGDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAgrawal N, 2019, THER ADV PSYCHOPHARM, V9, DOI 10.1177/2045125319862968eng
hcfmusp.relation.referenceAllgulander, 2022, PSYCH SCI SA, V5, P1eng
hcfmusp.relation.referenceAllgulander C, 2016, CURR OPIN PSYCHIATR, V29, P13, DOI 10.1097/YCO.0000000000000217eng
hcfmusp.relation.referenceAlonso J, 2004, ACTA PSYCHIAT SCAND, V109, P21eng
hcfmusp.relation.referenceAlonso J, 2007, J CLIN PSYCHIAT, V68, P3eng
hcfmusp.relation.referenceAlonso J, 2018, DEPRESS ANXIETY, V35, P195, DOI 10.1002/da.22711eng
hcfmusp.relation.referenceAmerican Psychiatric Association [APA], 2013, DIAGNOSTIC STAT MANUeng
hcfmusp.relation.referenceAmore M, 1999, HUM PSYCHOPHARM CLIN, V14, P429, DOI 10.1002/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.3.CO;2-Veng
hcfmusp.relation.referenceANDERSCH S, 1991, ACTA PSYCHIAT SCAND, V83, P18, DOI 10.1111/j.1600-0447.1991.tb03097.xeng
hcfmusp.relation.referenceAnderson RJ, 2002, INT J PSYCHIAT MED, V32, P235, DOI 10.2190/KLGD-4H8D-4RYL-TWQ8eng
hcfmusp.relation.referenceBakish D, 1996, PSYCHOPHARMACOL BULL, V32, P135eng
hcfmusp.relation.referenceBandelow B, 2018, BRIT J PSYCHIAT, V212, P333, DOI 10.1192/bjp.2018.49eng
hcfmusp.relation.referenceBandelow Borwin, 2017, World J Biol Psychiatry, V18, P162, DOI 10.1080/15622975.2016.1190867eng
hcfmusp.relation.referenceBandelow B, 2016, WORLD J BIOL PSYCHIA, V17, P321, DOI 10.1080/15622975.2016.1181783eng
hcfmusp.relation.referenceBandelow B, 2015, DIALOGUES CLIN NEURO, V17, P327eng
hcfmusp.relation.referenceBandelow B, 2015, INT CLIN PSYCHOPHARM, V30, P183, DOI 10.1097/YIC.0000000000000078eng
hcfmusp.relation.referenceBandelow Borwin, 2002, World J Biol Psychiatry, V3, P171, DOI 10.3109/15622970209150621eng
hcfmusp.relation.referenceBandelow B, 2008, WORLD J BIOL PSYCHIA, V9, P248, DOI 10.1080/15622970802465807eng
hcfmusp.relation.referenceBankier B, 2004, PSYCHOSOM MED, V66, P645, DOI 10.1097/01.psy.0000138126.90551.62eng
hcfmusp.relation.referenceBarterian JA, 2018, J PSYCHIATR PRACT, V24, P2, DOI 10.1097/PRA.0000000000000284eng
hcfmusp.relation.referenceAndre EB, 2020, PHARMACOEPIDEM DR S, V29, P1201, DOI 10.1002/pds.4932eng
hcfmusp.relation.referenceLepola UM, 1998, J CLIN PSYCHIAT, V59, P528, DOI 10.4088/JCP.v59n1006eng
hcfmusp.relation.referenceBLACK B, 1994, J AM ACAD CHILD PSY, V33, P1000, DOI 10.1097/00004583-199409000-00010eng
hcfmusp.relation.referenceBoudewyns PA, 1996, CLIN PSYCHOL PSYCHOT, V3, P185, DOI 10.1002/(SICI)1099-0879(199609)3:3<185::AID-CPP101>3.0.CO;2-0eng
hcfmusp.relation.referenceBouman WP, 1998, INT J GERIATR PSYCH, V13, P12, DOI 10.1002/(SICI)1099-1166(199801)13:1<12::AID-GPS718>3.3.CO;2-6eng
hcfmusp.relation.referenceBOYER W, 1995, INT CLIN PSYCHOPHARM, V10, P45, DOI 10.1097/00004850-199503000-00006eng
hcfmusp.relation.referenceBrenes GA, 2003, PSYCHOSOM MED, V65, P963, DOI 10.1097/01.PSY.0000097339.75789.81eng
hcfmusp.relation.referenceBunevicius R, 2006, CNS DRUGS, V20, P897, DOI 10.2165/00023210-200620110-00003eng
hcfmusp.relation.referenceBYSTRITSKY A, 1994, ANXIETY, V1, P287eng
hcfmusp.relation.referenceCahill SP, 1999, J ANXIETY DISORD, V13, P5, DOI 10.1016/S0887-6185(98)00039-5eng
hcfmusp.relation.referenceCaldirola D, 2020, EXPERT OPIN PHARMACO, V21, P1699, DOI 10.1080/14656566.2020.1779220eng
hcfmusp.relation.referenceCarlson JS, 1999, J CHILD ADOL PSYCHOP, V9, P293, DOI 10.1089/cap.1999.9.293eng
hcfmusp.relation.referenceLiebowitz M R, 1987, Mod Probl Pharmacopsychiatry, V22, P141eng
hcfmusp.relation.referenceCavaljuga Semra, 2003, Bosn J Basic Med Sci, V3, P27eng
hcfmusp.relation.referenceChamberlain SR, 2021, CNS DRUGS, V35, P703, DOI 10.1007/s40263-021-00832-xeng
hcfmusp.relation.referenceCHARNEY DS, 1986, J CLIN PSYCHIAT, V47, P580eng
hcfmusp.relation.referenceChen MH, 2016, PROG NEURO-PSYCHOPH, V70, P219, DOI 10.1016/j.pnpbp.2016.02.001eng
hcfmusp.relation.referenceChen TR, 2019, J PSYCHIATR RES, V118, P73, DOI 10.1016/j.jpsychires.2019.08.014eng
hcfmusp.relation.referenceCOHEN J, 1962, J ABNORM PSYCHOL, V65, P145, DOI 10.1037/h0045186eng
hcfmusp.relation.referenceCOLEMAN JH, 1992, BRIT J PSYCHIAT, V160, P191, DOI 10.1192/bjp.160.2.191eng
hcfmusp.relation.referenceCosta DLD, 2013, J PSYCHIATR RES, V47, P1700, DOI 10.1016/j.jpsychires.2013.07.006eng
hcfmusp.relation.referenceDavies SJC, 2004, BRIT MED J, V328, P939, DOI 10.1136/bmj.328.7445.939eng
hcfmusp.relation.referencede Lijster JM, 2017, CAN J PSYCHIAT, V62, P237, DOI 10.1177/0706743716640757eng
hcfmusp.relation.referenceManassis K, 2016, EUR CHILD ADOLES PSY, V25, P571, DOI 10.1007/s00787-015-0794-1eng
hcfmusp.relation.referenceDENBOER JA, 1988, INT CLIN PSYCHOPHARM, V3, P59, DOI 10.1097/00004850-198801000-00005eng
hcfmusp.relation.referenceDevilly GJ, 1998, BEHAV THER, V29, P435, DOI 10.1016/S0005-7894(98)80042-7eng
hcfmusp.relation.referenceDriessen E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137864eng
hcfmusp.relation.referenceDriessen J, 2020, CHILD PSYCHIAT HUM D, V51, P330, DOI 10.1007/s10578-019-00933-1eng
hcfmusp.relation.referenceDriot D, 2016, THERAPIE, V71, P575, DOI 10.1016/j.therap.2016.04.006eng
hcfmusp.relation.referenceEhlers A, 2014, AM J PSYCHIAT, V171, P294, DOI 10.1176/appi.ajp.2013.13040552eng
hcfmusp.relation.referenceEvoy KE, 2021, DRUGS, V81, P125, DOI 10.1007/s40265-020-01432-7eng
hcfmusp.relation.referenceFalkai P, 2005, WORLD J BIOL PSYCHIA, V6, P132, DOI 10.1080/15622970510030090eng
hcfmusp.relation.referenceFlint J, 2015, Psychol Med, V45, P439, DOI 10.1017/S0033291714001421eng
hcfmusp.relation.referenceFoa EB, 2018, JAMA-J AM MED ASSOC, V319, P354, DOI 10.1001/jama.2017.21242eng
hcfmusp.relation.referenceMancuso CE, 2004, PHARMACOTHERAPY, V24, P1177, DOI 10.1592/phco.24.13.1177.38089eng
hcfmusp.relation.referenceFrasure-Smith N, 2008, ARCH GEN PSYCHIAT, V65, P62, DOI 10.1001/archgenpsychiatry.2007.4eng
hcfmusp.relation.referenceFreire RC, 2017, J CLIN PSYCHOPHARM, V37, P429, DOI 10.1097/JCP.0000000000000740eng
hcfmusp.relation.referenceFurukawa TA, 2014, ACTA PSYCHIAT SCAND, V130, P181, DOI 10.1111/acps.12275eng
hcfmusp.relation.referenceFurukawa TA., 2019, COCHRANE DB SYST REV, V6eng
hcfmusp.relation.referenceGahr M, 2013, EUR J CLIN PHARMACOL, V69, P1335, DOI 10.1007/s00228-012-1464-6eng
hcfmusp.relation.referenceGibbons RD, 2007, AM J PSYCHIAT, V164, P1356, DOI 10.1176/appi.ajp.2007.07030454eng
hcfmusp.relation.referenceGlassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701eng
hcfmusp.relation.referenceGoddard AW, 2001, ARCH GEN PSYCHIAT, V58, P681, DOI 10.1001/archpsyc.58.7.681eng
hcfmusp.relation.referenceGomez AF, 2018, EXPERT OPIN PHARMACO, V19, P883, DOI 10.1080/14656566.2018.1472767eng
hcfmusp.relation.referenceGOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006eng
hcfmusp.relation.referenceMataix-Cols D, 2016, WORLD PSYCHIATRY, V15, P80, DOI 10.1002/wps.20299eng
hcfmusp.relation.referenceGrigoriadis S, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f6932eng
hcfmusp.relation.referenceGuy E., 1976, ECDEU ASS MAN PSYCH, P217eng
hcfmusp.relation.referenceHalaby A, 2015, CURR DRUG SAF, V10, P184, DOI 10.2174/1574886309666141022101956eng
hcfmusp.relation.referenceHAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.xeng
hcfmusp.relation.referenceHasan A, 2019, WORLD J BIOL PSYCHIA, V20, P2, DOI 10.1080/15622975.2018.1557346eng
hcfmusp.relation.referenceHeldt E, 2003, PSYCHOTHER PSYCHOSOM, V72, P43, DOI 10.1159/000067188eng
hcfmusp.relation.referenceHerring MP, 2012, PSYCHOTHER PSYCHOSOM, V81, P21, DOI 10.1159/000327898eng
hcfmusp.relation.referenceHetrick S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004851.pub2eng
hcfmusp.relation.referenceHolt RIG, 2013, J AFFECT DISORDERS, V150, P84, DOI 10.1016/j.jad.2013.02.026eng
hcfmusp.relation.referenceHrobjartsson A, 2013, CAN MED ASSOC J, V185, pE201, DOI 10.1503/cmaj.120744eng
hcfmusp.relation.referenceMAVISSAKALIAN M, 1992, ARCH GEN PSYCHIAT, V49, P318eng
hcfmusp.relation.referenceHuang YQ, 2019, LANCET PSYCHIAT, V6, P211, DOI 10.1016/S2215-0366(18)30511-Xeng
hcfmusp.relation.referenceIssari Y, 2016, J CLIN PSYCHIAT, V77, pE605, DOI 10.4088/JCP.14r09758eng
hcfmusp.relation.referenceJohnson EM, 2006, AM J GERIAT PSYCHIAT, V14, P796, DOI 10.1097/01.JGP.0000204328.50105.b3eng
hcfmusp.relation.referenceJones CW, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6104eng
hcfmusp.relation.referenceKessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593eng
hcfmusp.relation.referenceKessler RC, 2007, WORLD PSYCHIATRY, V6, P168eng
hcfmusp.relation.referenceKessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359eng
hcfmusp.relation.referenceKLEIN RG, 1992, J AM ACAD CHILD PSY, V31, P21, DOI 10.1097/00004583-199201000-00005eng
hcfmusp.relation.referenceKopp S, 1997, J CHILD PSYCHOL PSYC, V38, P257, DOI 10.1111/j.1469-7610.1997.tb01859.xeng
hcfmusp.relation.referenceLecrubier Y, 1997, ACTA PSYCHIAT SCAND, V95, P153, DOI 10.1111/j.1600-0447.1997.tb00389.xeng
hcfmusp.relation.referenceMay T, 2020, INT J DRUG POLICY, V82, DOI 10.1016/j.drugpo.2020.102823eng
hcfmusp.relation.referenceLepola U, 2003, J CLIN PSYCHIAT, V64, P654, DOI 10.4088/JCP.v64n0606eng
hcfmusp.relation.referenceLEPOLA U, 1990, Human Psychopharmacology, V5, P159, DOI 10.1002/hup.470050209eng
hcfmusp.relation.referenceMbaya P, 2007, HUM PSYCHOPHARM CLIN, V22, P129, DOI 10.1002/hup.834eng
hcfmusp.relation.referenceMcAllister-Williams RH, 2017, J PSYCHOPHARMACOL, V31, P519, DOI 10.1177/0269881117699361eng
hcfmusp.relation.referenceMikkelsen RL, 2004, NORD J PSYCHIAT, V58, P65, DOI 10.1080/08039480310000824eng
hcfmusp.relation.referenceBakker A, 1999, J CLIN PSYCHIAT, V60, P831, DOI 10.4088/JCP.v60n1205eng
hcfmusp.relation.referenceMoritz S, 2019, EUR ARCH PSY CLIN N, V269, P577, DOI 10.1007/s00406-018-0931-1eng
hcfmusp.relation.referenceNAGY LM, 1989, ARCH GEN PSYCHIAT, V46, P993eng
hcfmusp.relation.referenceNardi AE, 2011, BRAZ J MED BIOL RES, V44, P366, DOI 10.1590/S0100-879X2011007500020eng
hcfmusp.relation.referenceNardi AE, 2012, J CLIN PSYCHOPHARM, V32, P120, DOI 10.1097/JCP.0b013e31823fe4bdeng
hcfmusp.relation.referenceNardi AE, 2010, J CLIN PSYCHOPHARM, V30, P290, DOI 10.1097/JCP.0b013e3181dcb2f3eng
hcfmusp.relation.referenceNelson J, 1999, Can J Clin Pharmacol, V6, P69eng
hcfmusp.relation.referenceNutt DJ, 2008, J PSYCHOPHARMACOL, V22, P3, DOI 10.1177/0269881107086283eng
hcfmusp.relation.referenceNutt DJ, 2005, J PSYCHOPHARMACOL, V19, P123, DOI 10.1177/0269881105051987eng
hcfmusp.relation.referenceOlesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.xeng
hcfmusp.relation.referenceOtto MW, 2001, AM J PSYCHIAT, V158, P1989, DOI 10.1176/appi.ajp.158.12.1989eng
hcfmusp.relation.referenceBakker A, 1999, J AFFECT DISORDERS, V54, P189, DOI 10.1016/S0165-0327(98)00147-5eng
hcfmusp.relation.referenceOTTO MW, 1993, AM J PSYCHIAT, V150, P1485eng
hcfmusp.relation.referencePerna G, 2001, PHARMACOPSYCHIATRY, V34, P85, DOI 10.1055/s-2001-14283eng
hcfmusp.relation.referencePollack MH, 2014, AM J PSYCHIAT, V171, P44, DOI 10.1176/appi.ajp.2013.12101353eng
hcfmusp.relation.referencePollack MH, 2003, J PSYCHOPHARMACOL, V17, P276, DOI 10.1177/02698811030173009eng
hcfmusp.relation.referencePOLLACK MH, 1994, J CLIN PSYCHIAT, V55, P200eng
hcfmusp.relation.referencePOLLACK MH, 1993, J CLIN PSYCHOPHARM, V13, P257eng
hcfmusp.relation.referenceProcyshyn, 2019, CLIN HDB PSYCHOTROPIeng
hcfmusp.relation.referenceQuagliato LA, 2019, J PSYCHOPHARMACOL, V33, P1340, DOI 10.1177/0269881119859372eng
hcfmusp.relation.referenceREGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85eng
hcfmusp.relation.referenceRICKELS K, 1982, AM J PSYCHOTHER, V36, P358, DOI 10.1176/appi.psychotherapy.1982.36.3.358eng
hcfmusp.relation.referenceBaldwin DS, 2022, ADDICTION, V117, P1472, DOI 10.1111/add.15695eng
hcfmusp.relation.referenceRICKELS K, 1990, ARCH GEN PSYCHIAT, V47, P899eng
hcfmusp.relation.referenceRIZLEY R, 1986, PSYCHOPHARMACOL BULL, V22, P167eng
hcfmusp.relation.referenceRobinson L, 2020, PSYCHOTHER RES, V30, P79, DOI 10.1080/10503307.2019.1566676eng
hcfmusp.relation.referenceRogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700eng
hcfmusp.relation.referenceROMACH M, 1995, AM J PSYCHIAT, V152, P1161eng
hcfmusp.relation.referenceRoose SP, 2003, BIOL PSYCHIAT, V54, P262, DOI 10.1016/S0006-3223(03)00320-2eng
hcfmusp.relation.referenceRubio G, 2007, ACTA PSYCHIAT SCAND, V115, P372, DOI 10.1111/j.1600-0447.2006.00896.xeng
hcfmusp.relation.referenceRubio G, 2007, EUR PSYCHIAT, V22, P80, DOI 10.1016/j.eurpsy.2006.09.007eng
hcfmusp.relation.referenceSartori SB, 2019, PHARMACOL THERAPEUT, V204, DOI 10.1016/j.pharmthera.2019.107402eng
hcfmusp.relation.referenceScahill L, 2005, J CHILD ADOL PS NURS, V18, P86, DOI 10.1111/j.1744-6171.2005.00015.xeng
hcfmusp.relation.referenceBaldwin DS, 2009, HUM PSYCHOPHARM CLIN, V24, P269, DOI 10.1002/hup.1019eng
hcfmusp.relation.referenceSchiele MA, 2020, EUR NEUROPSYCHOPHARM, V33, P45, DOI 10.1016/j.euroneuro.2020.01.009eng
hcfmusp.relation.referenceSchneier FR, 2017, DEPRESS ANXIETY, V34, P1085, DOI 10.1002/da.22693eng
hcfmusp.relation.referenceSchwan S, 2010, EUR J CLIN PHARMACOL, V66, P947, DOI 10.1007/s00228-010-0853-yeng
hcfmusp.relation.referenceSchweizer E, 1998, PSYCHOL MED, V28, P713, DOI 10.1017/S0033291798006540eng
hcfmusp.relation.referenceSegool NK, 2008, DEPRESS ANXIETY, V25, P620, DOI 10.1002/da.20410eng
hcfmusp.relation.referenceSELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965eng
hcfmusp.relation.referenceSharp SC, 2006, CLIN DRUG INVEST, V26, P247, DOI 10.2165/00044011-200626050-00002eng
hcfmusp.relation.referenceShen BJ, 2008, J AM COLL CARDIOL, V51, P113, DOI 10.1016/j.jacc.2007.09.033eng
hcfmusp.relation.referenceSiegmann EM, 2018, JAMA PSYCHIAT, V75, P577, DOI 10.1001/jamapsychiatry.2018.0190eng
hcfmusp.relation.referenceSilberman E, 2021, BRIT J PSYCHIAT, V218, P125, DOI 10.1192/bjp.2020.164eng
hcfmusp.relation.referenceBandelow B, 2007, PHARMACOPSYCHIATRY, V40, P152, DOI 10.1055/s-2007-984398eng
hcfmusp.relation.referenceSimon GE, 2006, AM J PSYCHIAT, V163, P41, DOI 10.1176/appi.ajp.163.1.41eng
hcfmusp.relation.referenceSkapinakis P, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20430eng
hcfmusp.relation.referenceSpiegel DA, 1999, J CLIN PSYCHOPHARM, V19, p17S, DOI 10.1097/00004714-199912002-00004eng
hcfmusp.relation.referenceStein DJ, 2019, GLOBAL MENTAL HLTH P, V1steng
hcfmusp.relation.referenceTAYLOR CB, 1990, J CLIN PSYCHOPHARM, V10, P112, DOI 10.1097/00004714-199004000-00006eng
hcfmusp.relation.referenceTurner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779eng
hcfmusp.relation.referenceTyrer P, 2021, PSYCHOL MED, DOI 10.1017/S0033291721000878eng
hcfmusp.relation.referenceTyrer PJ., 2010, ENCY PSYCHOPHARMACOL, P218eng
hcfmusp.relation.referenceUHLENHUTH EH, 1989, J AFFECT DISORDERS, V17, P261, DOI 10.1016/0165-0327(89)90009-8eng
hcfmusp.relation.referenceVarigonda AL, 2016, J AM ACAD CHILD PSY, V55, P851, DOI 10.1016/j.jaac.2016.07.768eng
hcfmusp.relation.referenceBandelow B, 2004, J CLIN PSYCHIAT, V65, P405eng
hcfmusp.relation.referenceWade AG, 1997, BRIT J PSYCHIAT, V170, P549, DOI 10.1192/bjp.170.6.549eng
hcfmusp.relation.referenceWatts SE, 2015, J AFFECT DISORDERS, V175, P152, DOI 10.1016/j.jad.2014.12.025eng
hcfmusp.relation.referenceWeathers FW, 2018, PSYCHOL ASSESSMENT, V30, P383, DOI 10.1037/pas0000486eng
hcfmusp.relation.referenceWHO, 2017, WHO 11 REV INT CLASSeng
hcfmusp.relation.referenceWittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15, P357, DOI 10.1016/j.euroneuro.2005.04.012eng
hcfmusp.relation.referenceWOODS SW, 1992, J CLIN PSYCHOPHARM, V12, P32eng
hcfmusp.relation.referenceWorld Health Organization, 1993, ICD 10 CLASS MENT BEeng
hcfmusp.relation.referenceWorthington JJ, 1998, PSYCHOPHARMACOL BULL, V34, P199eng
hcfmusp.relation.referenceYang LN, 2019, EUR CHILD ADOLES PSY, V28, P79, DOI 10.1007/s00787-018-1189-xeng
hcfmusp.relation.referenceZhou XY, 2015, WORLD PSYCHIATRY, V14, P207, DOI 10.1002/wps.20217eng
hcfmusp.relation.referenceBandelow B, 2001, CAN J PSYCHIAT, V46, P948, DOI 10.1177/070674370104601007eng
hcfmusp.relation.referenceZohar J, 2014, EUR NEUROPSYCHOPHARM, V24, P1005, DOI 10.1016/j.euroneuro.2013.08.004eng
hcfmusp.relation.referenceZomahoun HTV, 2017, INT J EPIDEMIOL, V46, P589, DOI 10.1093/ije/dyw273eng
hcfmusp.relation.referenceBandelow B., 2003, HDB DEPRESSION ANXIE, P49eng
hcfmusp.relation.referenceBandelow B., 1999, PANIC AGORAPHOBIA SCeng
hcfmusp.relation.referenceBandelow B, 2023, WORLD J BIOL PSYCHIA, V24, P118, DOI 10.1080/15622975.2022.2086296eng
hcfmusp.relation.referenceBandelow B, 2022, BMC PSYCHIATRY, V22, DOI 10.1186/s12888-022-04002-1eng
hcfmusp.relation.referenceBandelow B, 2006, J CLIN PSYCHIAT, V67, P1428, DOI 10.4088/JCP.v67n0914eng
hcfmusp.relation.referenceBandelow B, 2006, CNS SPECTRUMS, V11, P21, DOI 10.1017/S1092852900025815eng
hcfmusp.relation.referenceBandelow B, 2022, EUR ARCH PSY CLIN N, V272, P571, DOI 10.1007/s00406-021-01324-1eng
hcfmusp.relation.referenceBandelow B, 2021, EUR NEUROPSYCHOPHARM, V49, P116, DOI 10.1016/j.euroneuro.2021.04.012eng
hcfmusp.relation.referenceBandelow B, 2020, ADV EXP MED BIOL, V1191, P347, DOI 10.1007/978-981-32-9705-0_19eng
hcfmusp.relation.referenceBandelow B, 2020, EUR ARCH PSY CLIN N, V270, P655, DOI 10.1007/s00406-018-0972-5eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationd4f77d76-d695-4f36-9635-4fe2fe184015
relation.isAuthorOfPublication587b0a62-5611-4071-ae48-19a46c43b55d
relation.isAuthorOfPublication.latestForDiscoveryd4f77d76-d695-4f36-9635-4fe2fe184015
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_BANDELOW_World_Federation_of_Societies_of_Biological_Psychiatry_WFSBP_2023.PDF
Tamanho:
663.67 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23